giovedì, 30 giugno 2022
Medinews
3 Luglio 2017

FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas

June 29, 2017 – The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). “This represents a major step forward for the hematology-oncology … (leggi tutto)

TORNA INDIETRO